Table III . Models available or in development at FORENAP. AD, Alzheimer's disease; CCK-4, cholecystokinin tetrapeptide; EEG, electroencephalography; ERP, event-related potential; fMRI, functional magnetic resonance imaging; MEG, magnetoencephalography.
| Indication | Method | Marker | Status |
| AD/cognition | |||
| Scopolamine | EEG/ERPs | Routine | |
| Lorazepam | EEG/ERPs | Routine | |
| Low-dose ketamine | EEG/ERPs | Validation underway | |
| Nonpharmacological method | fMRI | Validation underway | |
| Anxiety | |||
| Panic | CCK-4 | fMRI | Validation underway |
| Anticipatory | Behavioral | fMRI | validation underway |
| Depression | |||
| Tryptophan depletion | Sleep EEG | validation completed | |
| Schizophrenia | |||
| Apomorphine | EEG | Routine | |
| Ketamine | EEG/MEG | validation underway |